Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Morales, J., Wells, J., Donskov, F., Bjarnason, G. A., Lee, J., Knox, J. J., Beuselinck, B., Vaishampayan, U. N., Brugarolas, J., Broom, R., Bamias, A., Yuasa, T., Srinivas, S., Ernst, D., Pezaro, C., Wood, L., Kollmannsberger, C. K., Rini, B. I., Choueiri, T. K., Heng, D. AMER SOC CLINICAL ONCOLOGY. 2016View details for Web of Science ID 000378109100537